PPAR-γ Ligands Repress TGFβ-Induced Myofibroblast Differentiation by Targeting the PI3K/Akt Pathway: Implications for Therapy of Fibrosis
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Transforming growth factor beta (TGFβ) induced differentiation of human lung fibroblasts to myofibroblasts is a key event in the pathogenesis of pulmonary fibrosis. Although the typical TGFβ signaling pathway involves the Smad family of transcription factors, we have previously reported that peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands inhibit TGFβ-mediated differentiation of human lung fibroblasts to myofibroblasts via a Smad-independent pathway. TGFβ also activates the phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) pathway leading to phosphorylation of Akt(S473). Here, we report that PPAR-γ ligands, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and 15-deoxy-(12,14)-15d-prostaglandin J(2) (15d-PGJ(2)), inhibit human myofibroblast differentiation of normal and idiopathic pulmonary fibrotic (IPF) fibroblasts, by blocking Akt phosphorylation at Ser473 by a PPAR-γ-independent mechanism. The PI3K inhibitor LY294002 and a dominant-negative inactive kinase-domain mutant of Akt both inhibited TGFβ-stimulated myofibroblast differentiation, as determined by Western blotting for α-smooth muscle actin and calponin. Prostaglandin A(1) (PGA(1)), a structural analogue of 15d-PGJ(2) with an electrophilic center, also reduced TGFβ-driven phosphorylation of Akt, while CAY10410, another analogue that lacks an electrophilic center, did not; implying that the activity of 15d-PGJ(2) and CDDO is dependent on their electrophilic properties. PPAR-γ ligands inhibited TGFβ-induced Akt phosphorylation via both post-translational and post-transcriptional mechanisms. This inhibition is independent of MAPK-p38 and PTEN but is dependent on TGFβ-induced phosphorylation of FAK, a kinase that acts upstream of Akt. Thus, PPAR-γ ligands inhibit TGFβ signaling by affecting two pro-survival pathways that culminate in myofibroblast differentiation. Further studies of PPAR-γ ligands and small electrophilic molecules may lead to a new generation of anti-fibrotic therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 PPAR-γ ligands inhibit TGFβ-induced Akt phosphorylation and myofibroblast differentiation in a PPAR-γ-independent but electrophilic carbon-dependent manner. HLF cells were treated with indicated compounds and/or TGFβ (5ng/ml) for 48 hours. Immunoblots were performed to assess the expression of indicated proteins. Protein lysates from all the indicated samples were electrophoretically separated on the same gel, and representative lanes from a single experiment are shown here. A, the ability of PPAR-γ ligands (CDDO (1µM) and 15d-PGJ2 (5µM)) to reduce p-Akt was not altered upon GW9662-mediated inhibition of PPAR-γ. GW9662 (5µM) inhibits PPAR-γ activity by a covalent bond formation with PPAR-γ protein [36]. R.P. indicates relative changes in Akt phosphorylation compared to control sample, and R.E., relative changes in expression compared to control sample. B, PPAR-γ ligands contain electrophilic carbons. Here, positions of the electrophilic carbons in the structures of the compounds are marked. CAY10410 and PGA1 are structural analogues of 15-d-PGJ2. PGA1 has an electrophilic center but CAY10410 does not. DSPS, like CDDO, has two electrophilic centers. Cells were pre-treated with CAY10410 (5µM), PGA1 (10µM) and DSPS (10µM) for 30 minutes C, only compounds with an electrophilic carbon are able to reduce Akt phosphorylation, indicating that presence of an electrophilic carbon is essential for the observed reduction in the phosphorylation of Akt. All the experiments were performed in triplicate and representative images are shown here.](https://figures.cochat.ai/paper-figures/42fe33a117e847be83731e464fb63bd7/ppar-ligands-repress-tgf-induced-myofibroblast-differentiation-by-targeting-the-figure-3.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overexpression of SMAD3 enhances, whereas knockdown inhibits αSMA and extracellular matrix production in fibroblasts (45–48). Furthermore, fibroblast-specific deletion of SMAD3 reduces αSMA production and myofibroblast phenotype (49–52), for example, loss of SMAD3 lowers the number of activated myofibroblasts in cardiac fibrosis in vivo and reduces extracellular matrix production by myofibroblasts”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Integrin-regulated FAK–Src signaling in normal and cancer cells
Mitra, S. K., & Schlaepfer, D. D. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.011 · Cited by 1,590 · cited 1×
“However, it is widely accepted that integrins are able to activate TGFb [56] and FAK [57,58],”
BackgroundSime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Self-citationSignaling cross-talk between TGF-β/BMP and other pathways
Guo, X., & Wang, X.-F. (2009) · Cell Research · doi:10.1038/cr.2008.302 · Cited by 1,015 · cited 3×
“Binding of active TGFb to its receptor triggers several signaling pathways [8,9], including the well-characterized Smad pathway and the PI3K/Akt (phosphotidylinositol-3-kinase/Protein Kinase B/PKB) pathway [7,10,11].”
Background15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Calalb, M. B., Polte, T. R., & Hanks, S. K. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.954 · Cited by 985 · cited 1×
“Increase in phosphorylation of FAK correlates with its increased catalytic activity [20,21] and is required for the recruitment of p85, a regulatory subunit of PI3K [22].”
BackgroundInterleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk, C. D., Conrad, D., & Glass, C. K. (1999) · Nature · doi:10.1038/22572 · Cited by 855 · cited 1×
“, have shown that PPAR-γ ligands also have effects that are independent of PPAR-γ activity. To examine if inhibition of Akt phosphorylation by PPAR-γ ligands was dependent on the functional activity of PPAR-γ, we used a pharmacological approach involving a PPAR-γ antagonist GW9662, an irreversible PPAR-γ antagonist th…”
Method
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., Li, J., Tran, P. T., Kaimal, V., Huang, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003205 · Cited by 587
“Although PPARα-regulated lipid metabolism has not previously been shown to be protective against fibrosis in direct studies, the transcription factor PPARγ has been shown in several organs to protect against fibrosis(38), implying that regulation of lipid and fatty acid oxidation is critical in fibrotic responses to c…”
BackgroundTargeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Kottmann, R. M., Kulkarni, A. A., Smolnycki, K. A., Lyda, E., Dahanayake, T., Salibi, R., Honnons, S., Jones, C., Isern, N. G., Hu, J. Z., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0084oc · Cited by 415
“Primary human lung fibroblasts were cultured to subconfluence on glass chamber slides under standard conditions described above, and slides were prepared using aSMA (Sigma Aldrich) and Alexa Fluor 488 (Invitrogen, Carlsbad, CA) as previously described (33).”
MethodSelf-citation
Metadata
- Authors
- Kulkarni, A. A., Thatcher, T. H., Olsen, K. C., Maggirwar, S. B., Phipps, R. P., & Sime, P. J.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Sime, Patricia J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-06
- Volume
- 6
- Issue
- 1
- Pages
- e15909
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3017065
- OpenAlex
- W1991127474
- Cited by
- 189
- References
- 60
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 8 · 2023: 13 · 2022: 11 · 2021: 12 · 2020: 7 · 2019: 22 · 2018: 10 · 2017: 16 · 2016: 10 · 2015: 16 · 2014: 10 · 2013: 9 · 2012: 22
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Rochester
- National Institutes of Health (ES01247, ES-07026)
- National Heart, Lung, and Blood Institute (R03HL095402, F30HL097596, T32HL066988, HL075432-04S2, HL095402-02, HL075432-04S1, R01HL075432, HL075432)
- National Institute of Environmental Health Sciences (P30ES001247, T32ES007026)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- PPARγ ligands, TGF-beta signaling, myofibroblast differentiation, pulmonary fibrosis, idiopathic pulmonary fibrosis, PI3K/Akt signaling, Akt phosphorylation, CDDO, prostaglandin A1, FAK phosphorylation, lung fibroblasts
- MeSH terms
- Cell Differentiation, Fibrosis, Humans, Ligands, Phosphorylation, Signal Transduction, Transforming Growth Factor beta, PPAR gamma, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PPAR-γ Ligands Repress TGFβ-Induced Myofibroblast Differentiation by Targeting the PI3K/Akt Pathway: Implications for Therapy of Fibrosis. https://app.cochat.ai/papers/10.1371/journal.pone.0015909
- The paper
- Kulkarni, A. A., Thatcher, T. H., Olsen, K. C., Maggirwar, S. B., Phipps, R. P., & Sime, P. J. (2011). PPAR-γ Ligands Repress TGFβ-Induced Myofibroblast Differentiation by Targeting the PI3K/Akt Pathway: Implications for Therapy of Fibrosis. PLoS ONE. https://doi.org/10.1371/journal.pone.0015909
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.